Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study to evaluate combination rucaparib and sacituzumab govitecan in patients with metastatic triple-negative breast cancer and metastatic urothelial cancer

Trial Profile

Phase I/II study to evaluate combination rucaparib and sacituzumab govitecan in patients with metastatic triple-negative breast cancer and metastatic urothelial cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rucaparib (Primary) ; Sacituzumab govitecan (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 26 Feb 2019 According to a Clovis Oncology media release, the enrolment is expected to begin in 2019.
    • 08 Jun 2018 New trial record
    • 03 Jun 2018 According to a Clovis Oncology media release, Clovis Oncology and Immunomedics announce planned clinical collaboration for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top